Bu sayfanın çevirisi deneyseldir ve geliştirilme aşamasındadır. imlerinizi bekliyoruz!

Sartorius Stedim Biotech Gelecekteki Büyüme

Future kriter kontrolleri 4/6

Sartorius Stedim Biotech kazanç ve gelirin sırasıyla yıllık 30.3% ve 10.1% oranında artacağı tahmin edilmektedir. EPS'nin yıllık 29.1% oranında büyümesi beklenmektedir. Özkaynak kârlılığının 3 yıl içinde 13.3% olacağı tahmin edilmektedir.

Anahtar bilgiler

31.2%

Kazanç büyüme oranı

31.7%

EPS büyüme oranı

Life Sciences kazanç büyümesi	26.2%
Gelir büyüme oranı	10.5%
Gelecekteki özkaynak getirisi	13.8%
Analist kapsamı	Good
Son güncelleme	18 Oct 2024

Gelecekteki son büyüme güncellemeleri

Sartorius Stedim Biotech S.A. Just Missed Earnings - But Analysts Have Updated Their Models

Jul 21

Sartorius Stedim Biotech S.A. Just Missed EPS By 26%: Here's What Analysts Think Will Happen Next

Apr 21

Recent updates

Sartorius Stedim Biotech S.A.'s (EPA:DIM) Share Price Not Quite Adding Up

Oct 15

Does Sartorius Stedim Biotech (EPA:DIM) Have A Healthy Balance Sheet?

Aug 11

Sartorius Stedim Biotech S.A. Just Missed Earnings - But Analysts Have Updated Their Models

Jul 21

Estimating The Fair Value Of Sartorius Stedim Biotech S.A. (EPA:DIM)

Jul 12

Sartorius Stedim Biotech (EPA:DIM) Has A Somewhat Strained Balance Sheet

May 13

Sartorius Stedim Biotech S.A. Just Missed EPS By 26%: Here's What Analysts Think Will Happen Next

Apr 21

With A 26% Price Drop For Sartorius Stedim Biotech S.A. (EPA:DIM) You'll Still Get What You Pay For

Apr 20

Weak Statutory Earnings May Not Tell The Whole Story For Sartorius Stedim Biotech (EPA:DIM)

Feb 19

Sartorius Stedim Biotech S.A.'s (EPA:DIM) Popularity With Investors Is Clear

Dec 22

Is Sartorius Stedim Biotech (EPA:DIM) Using Too Much Debt?

Dec 01

Are Sartorius Stedim Biotech S.A. (EPA:DIM) Investors Paying Above The Intrinsic Value?

Nov 10

Are Sartorius Stedim Biotech S.A. (EPA:DIM) Investors Paying Above The Intrinsic Value?

Apr 23

Here's Why Sartorius Stedim Biotech (EPA:DIM) Can Manage Its Debt Responsibly

Feb 07

Does Sartorius Stedim Biotech (EPA:DIM) Deserve A Spot On Your Watchlist?

Jan 20

Sartorius Stedim Biotech (EPA:DIM) Has A Pretty Healthy Balance Sheet

Nov 09

Here's Why We Think Sartorius Stedim Biotech (EPA:DIM) Might Deserve Your Attention Today

Oct 20

Estimating The Fair Value Of Sartorius Stedim Biotech S.A. (EPA:DIM)

Oct 03

We Think Sartorius Stedim Biotech (EPA:DIM) Can Stay On Top Of Its Debt

Jul 26

Do Sartorius Stedim Biotech's (EPA:DIM) Earnings Warrant Your Attention?

Jul 09

Is Sartorius Stedim Biotech S.A. (EPA:DIM) Expensive For A Reason? A Look At Its Intrinsic Value

Jun 21

Sartorius Stedim Biotech (EPA:DIM) Could Easily Take On More Debt

Apr 21

Here's Why I Think Sartorius Stedim Biotech (EPA:DIM) Is An Interesting Stock

Apr 03

We Like Sartorius Stedim Biotech's (EPA:DIM) Earnings For More Than Just Statutory Profit

Feb 24

Kazanç ve Gelir Büyüme Tahminleri

ENXTPA:DIM - Analistlerin gelecek tahminleri ve geçmiş finansal verileri (EUR Millions )
Tarih	Gelir	Kazançlar	Serbest Nakit Akışı	Faaliyetlerden Nakit	Avg. Analist Sayısı
12/31/2026	3,364	451	395	842	12
12/31/2025	3,009	344	316	754	12
12/31/2024	2,785	220	290	668	11
9/30/2024	2,736	161	504	866	N/A
6/30/2024	2,747	170	305	706	N/A
3/31/2024	2,716	255	169	636	N/A
12/31/2023	2,776	310	273	746	N/A
9/30/2023	2,959	460	113	625	N/A
6/30/2023	3,170	635	162	675	N/A
3/31/2023	3,356	717	137	606	N/A
12/31/2022	3,493	876	182	612	N/A
9/30/2022	3,381	681	125	552	N/A
6/30/2022	3,259	625	193	584	N/A
3/31/2022	3,094	559	322	661	N/A
12/31/2021	2,887	414	378	702	N/A
9/30/2021	2,639	523	355	623	N/A
6/30/2021	2,393	469	367	590	N/A
3/31/2021	2,143	398	310	506	N/A
12/31/2020	1,910	336	258	417	N/A
9/30/2020	1,743	299	299	414	N/A
6/30/2020	1,600	255	243	365	N/A
3/31/2020	1,520	254	216	345	N/A
12/31/2019	1,441	235	174	310	N/A
9/30/2019	1,393	247	142	291	N/A
6/30/2019	1,336	238	21	261	N/A
3/31/2019	1,274	223	88	270	N/A
12/31/2018	1,212	208	51	227	N/A
9/30/2018	1,172	185	57	226	N/A
6/30/2018	1,121	173	N/A	225	N/A
3/31/2018	1,093	162	N/A	196	N/A
12/31/2017	1,081	161	N/A	175	N/A
9/30/2017	1,073	151	N/A	165	N/A
6/30/2017	1,089	157	N/A	169	N/A
3/31/2017	1,075	157	N/A	146	N/A
12/31/2016	1,052	154	N/A	157	N/A
9/30/2016	1,009	145	N/A	146	N/A
6/30/2016	971	142	N/A	129	N/A
3/31/2016	926	136	N/A	155	N/A
12/31/2015	884	118	N/A	143	N/A
9/30/2015	850	111	N/A	150	N/A
6/30/2015	781	89	N/A	128	N/A
3/31/2015	734	76	N/A	113	N/A
12/31/2014	684	72	N/A	111	N/A
9/30/2014	646	71	N/A	93	N/A
6/30/2014	620	67	N/A	110	N/A
3/31/2014	604	68	N/A	97	N/A
12/31/2013	588	66	N/A	90	N/A

Analist Gelecek Büyüme Tahminleri

Kazançlar ve Tasarruf Oranları: DIM 'nin tahmini kazanç büyümesi (yıllık 30.3% ) tasarruf oranının ( 1.2% ) üzerindedir.

Kazançlar ve Piyasa: DIM şirketinin kazançlarının (yıllık 30.3% ) French pazarından (yıllık 12.3% ) daha hızlı büyümesi öngörülüyor.

Yüksek Büyüme Kazançları: DIM şirketinin kazançlarının önümüzdeki 3 yıl içerisinde önemli ölçüde artması bekleniyor.

Gelir ve Pazar: DIM şirketinin gelirinin (yıllık 10.1% ) French pazarından (yıllık 5.7% ) daha hızlı büyümesi öngörülüyor.

Yüksek Büyüme Geliri: DIM şirketinin gelirinin (yıllık 10.1% ) yıllık 20% oranından daha yavaş büyümesi öngörülüyor.

Hisse Başına Kazanç Büyüme Tahminleri

Gelecekteki Özkaynak Getirisi

Gelecekteki ROE: DIM 'nin Özsermaye Getirisi'nin 3 yıl içinde düşük olması tahmin ediliyor ( 13.3 %).

Sartorius Stedim Biotech Gelecekteki Büyüme

Future kriter kontrolleri 4/6

Anahtar bilgiler

Gelecekteki son büyüme güncellemeleri

Price target decreased by 8.8% to €216

Consensus EPS estimates fall by 17%

Sartorius Stedim Biotech S.A. Just Missed Earnings - But Analysts Have Updated Their Models

Sartorius Stedim Biotech S.A. Just Missed EPS By 26%: Here's What Analysts Think Will Happen Next

Consensus EPS estimates fall by 26%

Price target decreased by 7.8% to €229

Recent updates

New minor risk - Earnings quality

Third quarter 2024 earnings: EPS and revenues miss analyst expectations

Sartorius Stedim Biotech S.A.'s (EPA:DIM) Share Price Not Quite Adding Up

Does Sartorius Stedim Biotech (EPA:DIM) Have A Healthy Balance Sheet?

Price target decreased by 8.8% to €216

Consensus EPS estimates fall by 17%

Sartorius Stedim Biotech S.A. Just Missed Earnings - But Analysts Have Updated Their Models

Second quarter 2024 earnings: EPS misses analyst expectations

New major risk - Financial position

Estimating The Fair Value Of Sartorius Stedim Biotech S.A. (EPA:DIM)

Now 23% overvalued

Sartorius Stedim Biotech (EPA:DIM) Has A Somewhat Strained Balance Sheet

Sartorius Stedim Biotech S.A. Just Missed EPS By 26%: Here's What Analysts Think Will Happen Next

With A 26% Price Drop For Sartorius Stedim Biotech S.A. (EPA:DIM) You'll Still Get What You Pay For

First quarter 2024 earnings: EPS and revenues miss analyst expectations

Upcoming dividend of €0.69 per share

Weak Statutory Earnings May Not Tell The Whole Story For Sartorius Stedim Biotech (EPA:DIM)

New minor risk - Profit margin trend

Dividend of €0.69 announced

Sartorius Stedim Biotech S.A. has filed a Follow-on Equity Offering in the amount of €1.2 billion.

Sartorius Stedim Biotech S.A. has filed a Follow-on Equity Offering in the amount of €1.2 billion.

Consensus EPS estimates fall by 26%

Sartorius Stedim Biotech S.A. to Report Nine Months, 2024 Results on Oct 17, 2024

Sartorius Stedim Biotech S.A.'s (EPA:DIM) Popularity With Investors Is Clear

Investor sentiment improves as stock rises 16%

Is Sartorius Stedim Biotech (EPA:DIM) Using Too Much Debt?

Price target decreased by 7.8% to €229

Are Sartorius Stedim Biotech S.A. (EPA:DIM) Investors Paying Above The Intrinsic Value?

Investor sentiment improves as stock rises 16%

Consensus EPS estimates fall by 25%

Price target decreased by 9.7% to €274

Third quarter 2023 earnings: EPS and revenues miss analyst expectations

Investor sentiment deteriorates as stock falls 18%

Does Sartorius Stedim Biotech (EPA:DIM) Have A Healthy Balance Sheet?

Consensus EPS estimates fall by 12%

Second quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Investor sentiment improves as stock rises 18%

Investor sentiment deteriorates as stock falls 16%

Price target decreased by 7.3% to €336

New minor risk - Share price stability

Consensus EPS estimates fall by 18%

Sartorius Stedim Biotech (EPA:DIM) Seems To Use Debt Quite Sensibly

Here's Why We Think Sartorius Stedim Biotech (EPA:DIM) Is Well Worth Watching

Consensus EPS estimates fall by 17%

Are Sartorius Stedim Biotech S.A. (EPA:DIM) Investors Paying Above The Intrinsic Value?

First quarter 2023 earnings: EPS and revenues miss analyst expectations

Upcoming dividend of €1.44 per share at 0.5% yield

Full year 2022 earnings released: EPS: €9.51 (vs €4.50 in FY 2021)

Here's Why Sartorius Stedim Biotech (EPA:DIM) Can Manage Its Debt Responsibly

Sartorius Stedim Biotech S.A. Provides Earnings Guidance for the Fiscal Year 2023

Does Sartorius Stedim Biotech (EPA:DIM) Deserve A Spot On Your Watchlist?

Sartorius Stedim Biotech S.A. to Report Fiscal Year 2022 Results on Jan 26, 2023

Sartorius Stedim Biotech S.A., Annual General Meeting, Mar 27, 2023

Less than half of directors are independent

Investor sentiment improved over the past week

Sartorius Stedim Biotech (EPA:DIM) Has A Pretty Healthy Balance Sheet

Third quarter 2022 earnings: EPS in line with expectations, revenues disappoint

Here's Why We Think Sartorius Stedim Biotech (EPA:DIM) Might Deserve Your Attention Today

Sartorius Stedim Biotech S.A. Provides Earnings Guidance for the Fiscal Year 2022

Estimating The Fair Value Of Sartorius Stedim Biotech S.A. (EPA:DIM)

Investor sentiment deteriorated over the past week

Sartorius Stedim Biotech S.A. (ENXTPA:DIM) entered into a definitive agreement to acquire Albumedix Ltd. from private investors for approximately £420 million.

We Think Sartorius Stedim Biotech (EPA:DIM) Can Stay On Top Of Its Debt

Second quarter 2022 earnings: EPS exceeds analyst expectations

Do Sartorius Stedim Biotech's (EPA:DIM) Earnings Warrant Your Attention?

Is Sartorius Stedim Biotech S.A. (EPA:DIM) Expensive For A Reason? A Look At Its Intrinsic Value

Consensus forecasts updated

First quarter 2022 earnings: EPS and revenues exceed analyst expectations

Less than half of directors are independent